Cargando…
The Association between Immune Checkpoint Proteins and Therapy Outcomes in Acute Myeloid Leukaemia Patients
SIMPLE SUMMARY: Despite promising results of clinical trials, the use of immune checkpoint inhibitors (ICI) in acute myeloid leukaemia (AML) remains limited. To date, the United States Food and Drug Administration (FDA) has approved two PD-1 inhibitors, namely nivolumab and pembrolizumab, for treati...
Autores principales: | Bolkun, Lukasz, Tynecka, Marlena, Walewska, Alicja, Bernatowicz, Malgorzata, Piszcz, Jaroslaw, Cichocka, Edyta, Wandtke, Tomasz, Czemerska, Magdalena, Wierzbowska, Agnieszka, Moniuszko, Marcin, Grubczak, Kamil, Eljaszewicz, Andrzej |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10526931/ https://www.ncbi.nlm.nih.gov/pubmed/37760457 http://dx.doi.org/10.3390/cancers15184487 |
Ejemplares similares
-
A Proliferation-Inducing Ligand and B-Cell Activating Factor Are Upregulated in Patients with Essential Thrombocythemia
por: Bolkun, Lukasz, et al.
Publicado: (2022) -
Secondary acute lymphoblastic leukaemia in a multiple myeloma patient
por: Piszcz, Jaroslaw, et al.
Publicado: (2013) -
Mesenchymal stem cells under epigenetic control – the role of epigenetic machinery in fate decision and functional properties
por: Walewska, Alicja, et al.
Publicado: (2023) -
Involvement of BAFF and APRIL in Resistance to Apoptosis of Acute Myeloid Leukemia
por: Bolkun, Lukasz, et al.
Publicado: (2016) -
Old Friends with Unexploited Perspectives: Current Advances in Mesenchymal Stem Cell-Based Therapies in Asthma
por: Tynecka, Marlena, et al.
Publicado: (2021)